



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Tenatumomab

Cat. No.:	HY-P99566
CAS No.:	1412891-40-7
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct <sup>131</sup> Iodine labeling approach [1][2].
<b>IC<sub>50</sub> &amp; Target</b>	tenascin-C <sup>[1][2]</sup>
<b>In Vitro</b>	Tenascin-C is a hexameric glycoprotein found in the extracellular matrix of embryos and adults. It has preferential expression in malignant solid tumors and hematologic tumors. Tenascin-C is spatially and temporally associated with tumor neovasculars and may exert anti-adhesion and immunosuppressive activities <sup>[2]</sup> . Tenatumomab (2-5 µg/mL; 16 h) retains immunoreactivity upon biotinylation. And Tenatumomab can be conjugated to up to 20 biotins per mAb, maintaining >50% immunoreactivity <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Tenatumomab (4 µg/mouse; i.v.; single dose) shows a biodistribution associated with low and high tenascin expression in nude mice transplanted with human HT-29 colon carcinoma and/or human U-118MG glioblastoma cells, respectively <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253.

[2]. De Santis R, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA